Hiroshi Kiyono Selected Research

Communicable Diseases (Infectious Diseases)

12/2021	Role of interleukin-6 in antigen-specific mucosal immunoglobulin A induction by cationic liposomes.
11/2021	Mucosal vaccines: wisdom from now and then.
1/2021	Development of Antibody-Fragment-Producing Rice for Neutralization of Human Norovirus.
1/2021	Enzymatically polymerised polyphenols prepared from various precursors potentiate antigen-specific immune responses in both mucosal and systemic compartments in mice.
1/2018	Cationic pullulan nanogel as a safe and effective nasal vaccine delivery system for respiratory infectious diseases.
1/2018	Intranasal vaccination against angiotensin II type 1 receptor and pneumococcal surface protein A attenuates hypertension and pneumococcal infection in rodents.
1/2017	Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.
4/2015	Novel transgenic rice-based vaccines.
1/2015	The mucosal immune system: From dentistry to vaccine development.
1/2015	Mucosal Immunosenescence in the Gastrointestinal Tract: A Mini-Review.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hiroshi Kiyono Research Topics

Disease

35	Inflammation (Inflammations) 01/2022 - 07/2002
26	Communicable Diseases (Infectious Diseases) 12/2021 - 09/2003
25	Infections 01/2022 - 10/2002
14	Diarrhea 01/2021 - 04/2004
13	Hypersensitivity (Allergy) 01/2021 - 12/2002
13	Colitis 01/2021 - 03/2002
9	Food Hypersensitivity (Food Allergy) 01/2021 - 01/2003
6	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2022 - 03/2002
5	Pneumococcal Infections 01/2021 - 01/2015
5	Immune System Diseases (Immune Disorders) 01/2020 - 01/2012
4	Cholera 01/2021 - 08/2009
4	Acquired Immunodeficiency Syndrome (AIDS) 01/2021 - 08/2007
4	Respiratory Tract Infections (Respiratory Tract Infection) 01/2018 - 08/2009
3	Contact Dermatitis (Eczema, Contact) 01/2020 - 01/2018
3	Crohn Disease (Crohn's Disease) 04/2014 - 03/2002
2	HIV Infections (HIV Infection) 01/2021 - 08/2007
2	Caliciviridae Infections 01/2021 - 01/2020
2	Bacterial Infections (Bacterial Infection) 07/2020 - 03/2007
2	Dermatitis 01/2020 - 04/2014
2	Pneumonia (Pneumonitis) 12/2019 - 01/2018
2	Asthma (Bronchial Asthma) 01/2019 - 10/2017
2	Neoplasms (Cancer) 01/2018 - 01/2018
2	Rotavirus Infections 04/2016 - 09/2013
2	Celiac Disease (Celiac Sprue) 04/2014 - 06/2010
2	Autoimmune Diseases (Autoimmune Disease) 01/2013 - 12/2005
2	Human Influenza (Influenza) 09/2012 - 10/2008
2	Botulism 11/2010 - 02/2005
2	Emerging Communicable Diseases (Emerging Infectious Diseases) 08/2009 - 10/2008
1	COVID-19 01/2022
1	Pancreatic Diseases (Pancreatic Disease) 01/2022
1	Sepsis (Septicemia) 01/2022
1	Bacillary Dysentery (Shigellosis) 01/2022
1	Disease Progression 01/2022
1	Dental Caries (Decay, Dental) 11/2021
1	Clostridium Infections 01/2021
1	Colorectal Neoplasms (Colorectal Cancer) 01/2021

Drug/Important Bio-Agent (IBA)

50	VaccinesIBA 12/2021 - 12/2002
19	AntigensIBA 12/2021 - 03/2002
14	CytokinesIBA 01/2022 - 03/2002
9	Immunoglobulin A (IgA)IBA 01/2021 - 10/2002
7	Adenosine Triphosphate (ATP)IBA 08/2018 - 01/2012
6	Cholera ToxinIBA 12/2019 - 12/2005
6	Secretory Immunoglobulin A (SIgA)IBA 01/2019 - 02/2007
6	Immunoglobulin E (IgE)IBA 06/2015 - 07/2002
5	Proteins (Proteins, Gene)FDA Link 01/2022 - 04/2004
5	AllergensIBA 10/2017 - 11/2005
5	Interleukin-10 (Interleukin 10)IBA 01/2012 - 03/2002
4	MicroRNAs (MicroRNA)IBA 01/2022 - 12/2015
4	LipidsIBA 01/2022 - 12/2013
4	polyethylene glycol polyethyleneimine nanogelIBA 11/2021 - 01/2013
4	Monoclonal AntibodiesIBA 11/2021 - 01/2003
4	OvalbuminIBA 01/2021 - 01/2009
4	pneumococcal surface protein AIBA 01/2021 - 01/2015
4	AntibodiesIBA 01/2021 - 08/2007
4	Peptides (Polypeptides)IBA 12/2005 - 03/2002
3	LipopolysaccharidesIBA 01/2021 - 07/2020
3	Phenobarbital (Luminal)FDA Link 01/2021 - 08/2007
3	Immunoglobulin G (IgG)IBA 01/2021 - 02/2007
3	Lipid AIBA 01/2021 - 07/2020
3	Therapeutic UsesIBA 01/2018 - 05/2004
3	Anti-Allergic Agents (Antiallergic Agents)IBA 01/2018 - 01/2009
3	Interleukin-4 (Interleukin 4)IBA 01/2017 - 01/2003
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2017 - 01/2003
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2014 - 07/2002
3	Interleukin-15 (Interleukin 15)IBA 04/2014 - 07/2002
3	DNA (Deoxyribonucleic Acid)IBA 01/2013 - 09/2004
3	Interleukin-12 Subunit p40IBA 06/2005 - 05/2003
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2022
2	EnzymesIBA 01/2022 - 10/2016
2	16S Ribosomal RNAIBA 01/2022 - 01/2021
2	Glycoproteins (Glycoprotein)IBA 01/2021 - 01/2019
2	Pharmaceutical PreparationsIBA 01/2021 - 01/2021
2	Vaccine AdjuvantsIBA 07/2020 - 09/2012
2	Immunoglobulin FragmentsIBA 01/2020 - 09/2013
2	ChemokinesIBA 11/2019 - 01/2012
2	Interleukin-6 (Interleukin 6)IBA 01/2019 - 09/2004
2	Galactoside 2-alpha-L-fucosyltransferase (Fucosyltransferase 2)IBA 01/2019 - 10/2016
2	Liposomes (Liposome)IBA 08/2018 - 01/2015
2	17,18-epoxy-5,8,11,14-eicosatetraenoic acidIBA 01/2018 - 06/2015
2	Interleukin-22 (IL-22)IBA 10/2017 - 06/2012
2	Interleukin-13IBA 01/2017 - 11/2005
2	VitaminsIBA 01/2015 - 12/2013
2	Purinergic Receptors (Receptors, Purine)IBA 01/2015 - 01/2012
2	Influenza Vaccines (Influenza Vaccine)FDA Link 09/2012 - 11/2002
2	Fingolimod Hydrochloride (FTY720)FDA Link 08/2007 - 05/2004
2	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 12/2005 - 11/2005
2	InterleukinsIBA 04/2005 - 01/2003
1	Ciprofloxacin (Cipro)FDA LinkGeneric 01/2022
1	Tetracycline (Achromycin)FDA LinkGeneric 01/2022
1	Hormones (Hormone)IBA 01/2022
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2022
1	Norfloxacin FDA Link 01/2022
1	InterferonsIBA 01/2022
1	HLA-B Antigens (HLA-B)IBA 01/2022
1	HLA-B57 antigenIBA 01/2022
1	HLA-A Antigens (HLA-A)IBA 01/2022
1	Biocompatible Materials (Biomaterials)IBA 11/2021

Therapy/Procedure

10	Therapeutics 01/2021 - 01/2003
6	Immunotherapy 01/2021 - 11/2005
2	Oral Administration 10/2011 - 01/2009